Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ONCR

Oncorus (ONCR) Stock Price, News & Analysis

Oncorus logo

About Oncorus Stock (NASDAQ:ONCR)

Advanced Chart

Key Stats

Today's Range
$0.13
$0.20
50-Day Range
$0.01
$0.13
52-Week Range
$0.01
$0.47
Volume
135,947 shs
Average Volume
1.33 million shs
Market Capitalization
$3.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Receive ONCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter.

ONCR Stock News Headlines

RFL Rafael Holdings, Inc.
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Comera Life Sciences Holdings Inc
Oncorus Inc Ordinary Shares
ONCR Historical Data
See More Headlines

ONCR Stock Analysis - Frequently Asked Questions

Oncorus, Inc. (NASDAQ:ONCR) announced its quarterly earnings results on Monday, May, 22nd. The company reported ($1.18) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.48.

Oncorus (ONCR) raised $87 million in an IPO on Friday, October 2nd 2020. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncorus investors own include Enterprise Products Partners (EPD), Aeglea BioTherapeutics (AGLE), Athenex (ATNX), Cheniere Energy (LNG), Atreca (BCEL), Fiserv (FI) and Brigham Minerals (MNRL).

Company Calendar

Last Earnings
5/22/2023
Today
5/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCR
Fax
N/A
Employees
64
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.33 per share
Price / Book
0.05

Miscellaneous

Free Float
21,633,000
Market Cap
$3.29 million
Optionable
Optionable
Beta
3.60
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ONCR) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners